Custom flow cytometry assays are critical to personalized medicine

Complex flow cytometry is crucial for modern personalized medicine. With 25 years of vast expertise in delivering flow cytometry testing for clinical trials that range from Phase I to Phase III, Cerba Research possesses an excellent history of designing and validating custom-made flow cytometry panels.

While a number of these are drug-specific and proprietary to the sponsor, Cerba Research also supplies off-the-shelf options.

At Cerba Research, you can rely on the development, validation, qualification and implementation of these assays on a global scale. With facilities in Europe, Asia-Pacific, the U.S., Australia and South Africa, Cerba Research is a significant lab that is known for its expertise and global leadership in flow cytometry methodology.

All Cerba’s instruments are standardized and cutting-edge, with up to 12 channels for ideal testing, and 24-color machines are coming to the market soon. Global standardization procedures and acceptance criteria defined on Cerba’s 8- and 10-color equipment guarantees reproducibility and consistency.

From test request to reporting the results, Cerba Research’s completely integrated clinical trial management system (CTMS) secures data transfer.

State-of-the-art instruments for flow cytometry

  • BD FACSCanto™ II
  • Navios – Beckman Coulter

Scientist-to-scientist interaction generates ideal panel design and project-adapted reportables

Cerba’s devoted flow cytometry team works in collaboration with the customer to design fit-for-purpose assays — validated panels across an extensive range of diseases. These proficient experts decipher complex clinical and safety data, offering unparalleled value with proven excellence in enhancing assay quality.

Custom solutions to solve complicated challenges and enhance workflows

From panel design to review of data, customers can gain custom-designed methods to accurately measure:

  • Hematologic malignancies
  • Immune cell phenotypes
  • Immune cell activation
  • Output in relative percentages, absolute count and fluorescence
  • Receptor occupancy and density

Besides customized panels, Cerba also offers a number of off-the-shelf options, such as a multiple myeloma panel. For additional details, and since new tests are frequently added, contact Cerba Research directly for a complete list of biomarkers.

CerbACT Asia - Immuno-Oncology Center of Excellence

Complex flow cytometry is vital for modern-day personalized medicine. That is why Cerba Research increased its flow cytometry services by introducing CerbACT Asia, the immuno-oncology Center of Excellence.

As well as innovative flow cytometry technology, CerbACT Asia also offers histopathology, multiplex immuno-histochemistry (IHC), PBMC and cell isolations.

Partnering with cerba will enable customers to transform the face of clinical development.

As a partner, Cerba Research helps its customers provide new, life-changing therapies to patients across the world.

Custom flow cytometry assays are critical to personalized medicine

Nithianandan Selliah, Ph.D. Head of Flow Cytometry. Image Credit: Cerba Research

Custom flow cytometry assays are critical to personalized medicine

Ans De Beuckelaer, Ph.D. Principal Scientist. Image Credit: Cerba Research

Custom flow cytometry assays are critical to personalized medicine

Richard Chang. Principal Scientist. Image Credit: Cerba Research

About Cerba Research

For over 35 years, Cerba Research has been setting the industry standard for exemplary clinical trial conduct. Today, across five continents, with a focus on precision medicine, we are changing the paradigm of the central lab’s role in complex clinical research.

From protocol inception through development and to market, our passionate experts deliver the highest quality specialized and personalized laboratory and diagnostic solutions. Partner with us for the most efficient strategy to actualize your biotech and pharmaceutical products sooner and improve the lives of patients worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 13, 2022 at 12:04 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerba Research. (2022, April 13). Custom flow cytometry assays are critical to personalized medicine. News-Medical. Retrieved on December 04, 2022 from https://www.news-medical.net/whitepaper/20220405/Custom-flow-cytometry-assays-are-critical-to-personalized-medicine.aspx.

  • MLA

    Cerba Research. "Custom flow cytometry assays are critical to personalized medicine". News-Medical. 04 December 2022. <https://www.news-medical.net/whitepaper/20220405/Custom-flow-cytometry-assays-are-critical-to-personalized-medicine.aspx>.

  • Chicago

    Cerba Research. "Custom flow cytometry assays are critical to personalized medicine". News-Medical. https://www.news-medical.net/whitepaper/20220405/Custom-flow-cytometry-assays-are-critical-to-personalized-medicine.aspx. (accessed December 04, 2022).

  • Harvard

    Cerba Research. 2022. Custom flow cytometry assays are critical to personalized medicine. News-Medical, viewed 04 December 2022, https://www.news-medical.net/whitepaper/20220405/Custom-flow-cytometry-assays-are-critical-to-personalized-medicine.aspx.

Other White Papers by this Supplier